Infection, Bacterial clinical trials at UC Davis
1 research study open to eligible people
A Study of the Combination of Experimental AR-301 and Antibiotics for Staphylococcus Aureus Ventilator-Associated Pneumonia
open to eligible people ages 18 years and up
AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.
Sacramento, California and other locations
Last updated: